Min-Jung Lee1, Yusuke Tomita1, Akira Yuno1, Sunmin Lee1, Nacer E Abrouk2, Bryan Oronsky3, Scott Caroen3, Jane B Trepel1. 1. Developmental Therapeutics Branch, Center for Cancer Research, National Cancer Institute (NCI), National Institutes of Health (NIH) , Bethesda, MD, USA. 2. Department of Clinical Research, Clinical Trial Innovations , Mountain View, CA, USA. 3. Department of Clinical Research, EpicentRx, Inc , La Jolla, CA, USA.
Abstract
Background: In a Phase II study RRx-001 was combined with Etoposide platinum (EP) in previously platinum treated SCLC. We correlated expression of the M2 marker, CD206, on HLA-DRlow/- monocytes, a phenotype that correlates with a poor prognosis, with response to RRx-001. Research design and methods: Patients received 4 mg RRx-001 once weekly until progression followed by the start of EP (etoposide 100 mg/m2 IV on days 1-3 of a 21-day cycle and either cisplatin 80 mg/m2 IV on day 1 or carboplatin AUC 5-6 IV on day 1). Treatment continued until progression or intolerable toxicity. Peripheral blood was collected in Cell Preparation Tubes with sodium citrate from 14 patients for exploratory studies during screening and after therapy on Days 1, 8, and 15. Peripheral blood mononuclear cells (PBMCs) were isolated from blood by centrifugation and multiparameter flow cytometric analysis was performed. Results: CD206 expression on HLA-DRlow/- monocytes was associated with response to chemotherapy and overall survival. Conclusion: During treatment with RRx-001, reduced expression of the protumorigenic M2 marker CD206 on peripheral monocytes positively correlated with increased response and survival.
Background: In a Phase II study RRx-001 was combined with Etoposide platinum (EP) in previously platinum treated SCLC. We correlated expression of the M2 marker, CD206, on HLA-DRlow/- monocytes, a phenotype that correlates with a poor prognosis, with response to RRx-001. Research design and methods: Patients received 4 mg RRx-001 once weekly until progression followed by the start of EP (etoposide 100 mg/m2 IV on days 1-3 of a 21-day cycle and either cisplatin 80 mg/m2 IV on day 1 or carboplatin AUC 5-6 IV on day 1). Treatment continued until progression or intolerable toxicity. Peripheral blood was collected in Cell Preparation Tubes with sodium citrate from 14 patients for exploratory studies during screening and after therapy on Days 1, 8, and 15. Peripheral blood mononuclear cells (PBMCs) were isolated from blood by centrifugation and multiparameter flow cytometric analysis was performed. Results: CD206 expression on HLA-DRlow/- monocytes was associated with response to chemotherapy and overall survival. Conclusion: During treatment with RRx-001, reduced expression of the protumorigenic M2 marker CD206 on peripheral monocytes positively correlated with increased response and survival.
Authors: Tony Reid; Bryan Oronsky; Jan Scicinski; Curt L Scribner; Susan J Knox; Shoucheng Ning; Donna M Peehl; Ron Korn; Meaghan Stirn; Corey A Carter; Arnold Oronsky; Michael J Taylor; William L Fitch; Pedro Cabrales; Michelle M Kim; Howard A Burris; Christopher D Lao; Nacer E D Abrouk; Gary R Fanger; Jeffrey R Infante Journal: Lancet Oncol Date: 2015-08-19 Impact factor: 41.316
Authors: T Yazawa; H Kamma; M Fujiwara; M Matsui; H Horiguchi; H Satoh; M Fujimoto; K Yokoyama; T Ogata Journal: J Pathol Date: 1999-01 Impact factor: 7.996
Authors: Daniel Morgensztern; Michal Rose; Saiama N Waqar; John Morris; Patrick C Ma; Thomas Reid; Christina E Brzezniak; Karen G Zeman; Arvinda Padmanabhan; JoAnn Hirth; Alexander I Spira; Jane B Trepel; Sukhmani K Padda Journal: Br J Cancer Date: 2019-06-24 Impact factor: 7.640